Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06390956
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-17
Brief Title:
Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma RPirto in Newly Diagnosed MZL
Sponsor:
Narendranath Epperla
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-23307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Narendranath Epperla
Lead Sponsor Class:
OTHER
Responsible Party:
Narendranath Epperla
Responsible Party Title:
Principal Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Eli Lilly and Company | INDUSTRY |